Skip to main content
Contact Locations Diversity Pro Bono Why Wolf

Three Wolf Greenfield Attorneys Named to IAM Strategy 300

3 min read

Three Wolf Greenfield shareholders have been included in the 2026 edition of the IAM Strategy 300: The World’s Leading IP Strategists. This guide identifies top practitioners who are taking IP portfolio management to the next level by leading the way in developing and implementing strategies that maximize the value of IP portfolios.

Scott focuses his practice on post-grant patent counseling and litigation matters at the US Patent and Trademark Office (USPTO) and related appeals to the US Court of Appeals for the Federal Circuit (CAFC). Scott handles all aspects of post-issuance patent proceedings, with a particular focus on administrative trials before the Patent Trial and Appeal Board (PTAB), such as inter partes review (IPR), post-grant review (PGR), and patent reexamination. He also provides advice on USPTO post-grant proceedings concurrent with complex International Trade Commission (ITC) and district court litigations. Scott is one of the most active PTAB trial attorneys in the US, having handled more than 500 PTAB matters, including competitor disputes in which significant market share/damage liability was at stake (e.g., $500 million+). He currently serves as lead post-grant counsel to some of the world’s best-known innovators. Scott also serves as an adjunct professor at the George Washington University School of Law in Washington, DC.

Rob develops strategies for life science companies to maximize exclusivity for therapeutic and diagnostic products. He assists clients with building global patent portfolios aligned with product life cycle, and advises clients on regulatory exclusivities, patent term extensions, Orange Book listings, and biosimilars. In addition to pharma and biotech companies, Rob works with universities, research institutions, and venture capital investors, providing patentability and freedom-to-operate assessments, non-infringement and invalidity opinions, performing IP diligence, and preparing agreements. He regularly counsels federal grant recipients and contractors with Bayh-Dole compliance, including use of iEdison. Rob has worked extensively in technologies including antibodies, vaccines, chimeric antigen receptors, cell therapies, synthetic biology, medical devices, imaging agents, biologics, and small molecules for new disease indications.

Nathan is a trial and appellate lawyer focusing on complex patent litigation and post-grant matters. As head of the firm’s Appellate Practice, Nathan has argued more than a dozen appeals at the United States Court of Appeals for the Federal Circuit and has served as lead counsel in many more. Nathan has also actively managed more than 50 matters before the Patent Trial and Appeal Board (PTAB) and regularly represents clients in federal district courts across the country as well as the United States International Trade Commission (ITC). Nathan’s deep knowledge of the law and ability to learn new technologies quickly have allowed him to assist clients in protecting their most critical inventions across a wide spectrum of technologies. Nathan has litigated cases involving technologies ranging from bionic prosthetics and orthopedic screws to wireless networks, data protection, and computer processors. From 2009–2010, Nathan clerked for the Honorable Arthur J. Gajarsa of the United States Court of Appeals for the Federal Circuit.

IAM Strategy 300 honorees come from service providers, corporations, research institutions, and universities, and are identified primarily through confidential online nominations, supplemented by interviews and email exchanges with senior members of the global IP community. To qualify, an individual must be nominated by at least three people outside their own organization, and further research must confirm exceptional skill and profound insight into developing, creating, and managing IP value.
Top